AB与Dalton合作开发抗体药物共轭物的质谱分析方法
AB Sciex和Dalton Pharma Services8月26号表示,他们已经达成合作,将协作开发抗体药物共轭物的分析方法。合作重点是发展共轭分子化学结构的质谱分析工作流程。 &ldquo 成功开发抗体药物共轭物面临的一个关键挑战是理解最终分子的结构和有效负载,&rdquo Dalton化学经理Tan Quach在一份声明中说。&ldquo 确定药物在特定抗体分子上的结合位置,以及结合的分子数量是新的ADC药物可能成功的一个重要指标。&rdquo &ldquo 质谱的最新进展为理解生物基质中ADC药物开发和工作机制等挑战问题提供了解决方案,&rdquo AB Sciex 公司LC / MS业务副总裁Chris Radloff说,&ldquo 利用这些分子很困难,通过形成这种合作,ADC开发者可以减少并发症,获得准确的结果,最终行成更安全、更有效的治疗方法。&rdquo 这项研究将使用AB Sciex 的TripleTOF 5600 + Selexion技术和TripleTOF 6600平台。 Dalton Pharma Services Dalton is a contract pharmaceutical manufacturer which provides completely integrated chemistry, development, and manufacturing to biotechnology and pharmaceutical clients around the world. In its 42,000 sq. ft. facility, Dalton operates cGMP manufacturing of Active Pharmaceutical Ingredients (APIs), sterile injectables, finished drug products in vials or syringes, as well as solid oral dosage forms. APIs can be produced in gram to kilogram quantities, including sterile APIs. Dalton contract capabilities can support you at any stage of the regulatory process (Phase I, II, III, or commercial). Development services include chemistry and process development, medicinal chemistry, custom drug conjugation, targeted drug delivery systems, analytical method development and validation, ICH stability testing, formulation, and polymorphism screening. Dalton also supports the industry' s pharmaceutical research programs with a catalog of 1400+ reference standards, building blocks, metabolites, and impurities with its Dalton Research Molecules business.